|
Biotech Holdings finalizes plans for launch of Sucanon diabetes drug in Mexico Wednesday, March 31, 2004 09:01 ET VANCOUVER, Mar 31, 2004 /PRNewswire-FirstCall via COMTEX/ -- Robert Rieveley, President of Biotech Holdings (the "Company", TSX-VEN: BIO.V; OTC BB: BIOHF) announced that the Company is finalizing plans for the launch in Mexico of its diabetes drug, Sucanon. "We are now discussing, with a Mexican marketing partner, the details of an agreement for distribution of Sucanon to national pharmacy chains in Mexico, combined with medical symposia to deliver information about Sucanon therapy to doctors and pharmacists. At the same time, to make the Mexican public aware of the benefits of Sucanon, we are planning extensive advertising of Sucanon on television and radio throughout Mexico," Mr. Rieveley said. "Our goal is a national launch of Sucanon in Mexico. Accordingly, together with reaching doctors and pharmacists with medical information about Sucanon, we are planning to simultaneously make the public aware, through television and radio advertising, that Sucanon, an important new drug for treatment of Type II symptoms, is now available through pharmacy chains in all regions of Mexico," Mr. Rieveley said. "World Health Organization data indicate that over 14% of Mexican adults suffer from Type II Diabetes. With a population of over 110 million, Mexico is accordingly one of the largest markets in the world for Type II Diabetes drugs. In terms of the number of Type II diabetics, Mexico City alone has more than all of Canada," Mr. Rieveley noted. Biotech Holdings` Sucanon is a new drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance. The drug is an insulin-receptor sensitizer, a class of drugs for controlling the chronically high blood sugar levels that typify diabetes by improving the receptivity of the cell wall to glucose uptake. The drug, in tablet form, works by improving patients` ability to utilize insulin, the hormone that controls blood sugar levels. Type II Diabetes affects more than 18 million people in North America, over 30 million in Latin America and nearly 200 million worldwide. Biotech Holdings has received regulatory approval for sale of the drug in Mexico and Peru as a treatment of Type II Diabetes symptoms. Biotech Holdings has also signed distribution agreements for the drug for Chile, Venezuela, Columbia and Argentina and plans to make regulatory applications for Sucanon in these jurisdictions as well as in Brazil. If you would you would like to be added to Biotech Holdings` email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp Biotech Holdings Ltd.`s head office is in Richmond, British Columbia. Biotech Holdings` shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech`s website at www.biotechltd.com. SOURCE Biotech Holdings Ltd. CONTACT: For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech`s website at www.biotechltd.com. To request a free copy of this organization`s annual report, please go to http://www.newswire.ca and click on reports@cnw. (BIO. BIOHF) http://www.prnewswire.com JS200 |
|
| aus der Diskussion: | Biotech Holdings Ltd (OTCBB:BIOHF) die neue Perle in Sachen DIABETIS |
| Autor (Datum des Eintrages): | js200 (05.04.04 19:47:56) |
| Beitrag: | 1 von 42 (ID:12660334) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |